How True Open Innovation TM and its global network can expand the opportunity for drug development by increasing efficiency and decreasing costs
Luca Rastelli, PhD
Boston Strategics Corporation
October, 2013
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
Biotechnology consulting refers to the practice of organization involved in Pacificlinkconsulting services contact: San Diego, CA 92127 Phone: 858-335-1300
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
Biotechnology consulting refers to the practice of organization involved in Pacificlinkconsulting services contact: San Diego, CA 92127 Phone: 858-335-1300
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.
Pharma Focus Asia, the leading Pharma Magazine in the industry, provides the latest issue 29 that discusses latest trends happening in the pharma industry. Explore our latest issue to enhance your knowledge. Check our Digital Magazine here: https://goo.gl/FHDDtt
Presented: 13th February 2019
Enabling successful project delivery through Virtual R&D
We enable UK life science companies to develop their drug discovery projects.
If you are an SME with a drug discovery project, or a CRO with expertise to provide, join this webinar and find out how we can help you.
Agenda:
- Introduction to Medicines Discovery Catapult
- What is Virtual R&D?
- The CRO Network
- The Expert Network
- The Benefits for SMEs and CROs / Experts
- Summary and time for questions
The 10 Most Innovative Pharma and Biotech Solution Providers, 2020 September ...Merry D'souza
The 10 most innovative pharma and biotech solution providers, 2020 september 2020; Insights Success has published The 10 most innovative pharma and biotech solution providers.
World ADC Frankfurt 2015 - sample brochureWorld ADC
The World ADC Frankfurt meeting has been established with the simple mission of speeding up the development of more potent and safe antibody drug conjugates.
Learn not only how to make an ADC, but how to make a great one. With insights on numerous novel payload technologies, robust strategies for preclinical evaluation and emerging clinical data, there is no better opportunity to accelerate your research.
Need for an Integrated approach to Formulation Research and Knowledge ManagementAjaz Hussain
1. Confidence in Generics: Need for an Integrated
approach to Formulation Research and Knowledge
Management (Ajaz Hussain)
2. Mechanism for an integrated approach to Formulation
Research, Knowledge Management, & Knowledge
sharing with FDA & Industry (Steve Byrn)
3. Integrated approach for evolving standards for
formulation design - case example NTI's (Ken Morris)
4. Integrated approach for evolving standard for analytical
characterization - case example excipient variability
(Eric Munson)
How to Work Effectively with Research Teams in New Product PlanningAnthony Russell
Presented at the 3rd New Product Planning Summit. The presentation was designed to help professionals in New Product Planning to present a case for why commercial strategy input is needed early in the process of developing new therapeutics. The presentation also includes suggested approaches and tools to help with effective engagement with Research teams.
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.
Pharma Focus Asia, the leading Pharma Magazine in the industry, provides the latest issue 29 that discusses latest trends happening in the pharma industry. Explore our latest issue to enhance your knowledge. Check our Digital Magazine here: https://goo.gl/FHDDtt
Presented: 13th February 2019
Enabling successful project delivery through Virtual R&D
We enable UK life science companies to develop their drug discovery projects.
If you are an SME with a drug discovery project, or a CRO with expertise to provide, join this webinar and find out how we can help you.
Agenda:
- Introduction to Medicines Discovery Catapult
- What is Virtual R&D?
- The CRO Network
- The Expert Network
- The Benefits for SMEs and CROs / Experts
- Summary and time for questions
The 10 Most Innovative Pharma and Biotech Solution Providers, 2020 September ...Merry D'souza
The 10 most innovative pharma and biotech solution providers, 2020 september 2020; Insights Success has published The 10 most innovative pharma and biotech solution providers.
World ADC Frankfurt 2015 - sample brochureWorld ADC
The World ADC Frankfurt meeting has been established with the simple mission of speeding up the development of more potent and safe antibody drug conjugates.
Learn not only how to make an ADC, but how to make a great one. With insights on numerous novel payload technologies, robust strategies for preclinical evaluation and emerging clinical data, there is no better opportunity to accelerate your research.
Need for an Integrated approach to Formulation Research and Knowledge ManagementAjaz Hussain
1. Confidence in Generics: Need for an Integrated
approach to Formulation Research and Knowledge
Management (Ajaz Hussain)
2. Mechanism for an integrated approach to Formulation
Research, Knowledge Management, & Knowledge
sharing with FDA & Industry (Steve Byrn)
3. Integrated approach for evolving standards for
formulation design - case example NTI's (Ken Morris)
4. Integrated approach for evolving standard for analytical
characterization - case example excipient variability
(Eric Munson)
How to Work Effectively with Research Teams in New Product PlanningAnthony Russell
Presented at the 3rd New Product Planning Summit. The presentation was designed to help professionals in New Product Planning to present a case for why commercial strategy input is needed early in the process of developing new therapeutics. The presentation also includes suggested approaches and tools to help with effective engagement with Research teams.
This is a level 200 - 300 presentation.
It assumes:
Good understanding of vCenter 4, ESX 4, ESXi 4.
Preferably hands-on
We will only cover the delta between 4.1 and 4.0
Overview understanding of related products like VUM, Data Recovery, SRM, View, Nexus, Chargeback, CapacityIQ, vShieldZones, etc
Good understanding of related storage, server, network technology
Target audience
VMware Specialist: SE + Delivery from partners
Presentación de la ponencia "Productividad colectiva" dentro de las jornadas técnicas tituladas "Más productividad, menos estrés" organizadas por Grupo Euroformac. Junio 2015
Software para la Inteligencia Tecnológica de Patentesminiera
Este informe estudia la oferta y la demanda de los programas que tienen por finalidad la explotación de los sistemas de patentes. Como hemos podido apreciar en la revisión bibliográfica anterior, no parece existir según trabajo que tenga una base empírica de estudio obteniendo información de los usuarios de las patentes. En este trabajo la evaluación se ha realizado cruzando dos estudios independientes que utilizan la misma estructura de base.
Las razones que nos han motivado a realizar este estudio pionero pueden ser resumidas en los siguientes puntos:
- Inexistencia de estudios exhaustivos que comparen las aplicaciones informáticas de análisis de patentes.
- La falta de estudios acerca de la demanda de los programas para el análisis de las patentes. Es decir, que no se conoce el uso y el valor que se asocia a las características ofrecidas por los productores de esta clase de aplicaciones informáticas.
- Inexistencia de una comparación de las aplicaciones con la necesidad demostrada por los usuarios de dichos productos.
- Obtener una valoración de la magnitud y el crecimiento de la oferta. Hemos contabilizado en el mercado más de 21 aplicaciones.5 Este número representa, en nuestra opinión, una oferta amplia en este campo especializado. Otra tendencia que destaca es que existe un crecimiento, aunque modesto, de la oferta de este tipo de aplicaciones.
- Nos encontramos con una alta variedad de la oferta de aplicaciones informáticas para la ICT. Una aplicación puede llegar a tener un número muy alto de características. Sin embargo, las aplicaciones existentes en la actualidad en el mercado incluyen diferentes grupos de características y por tanto es difícil llevar a cabo una comparación parcial de las mismas. Por tanto creemos que es necesaria una normalización o un enfoque uniforme en el estudio de estas aplicaciones para que la comparación sea válida.
Great Articles, news and expertise from leadership, HR and People development experts around the world. Come and see our great new e.MILE Magazine here: http://www.peopledevelopmentmagazine.com
How and When to Kill a Program in New Product PlanningAnthony Russell
Presented at the 4th New Product Planning Summit in Boston (Dec 2 -3 , 2019). Presentation covers why weak programs should be cut from pharmaceutical and biotech pipelines, what defines a "weak" program, and describes objective methods to evaluate programs to help prioritize assets.
5th Annual Pre-Filled Syringes East CoastTeri Arri
Building on the success of previous sell-out shows, SMi Group is delighted to announce the return of the 5th annual conference and exhibition: Pre-Filled Syringes - East Coast, taking place on April 11th – 12th 2018 in Boston, Massachusetts, USA.
A rise in chronic diseases, improvements in technology and a growing demand for easy to use drug administration products has in recent years, created a booming Pre-Filled Syringes industry.
Some notable areas of increased attention have been the broader trends for combination products and biologics, as well as the move towards digital health and improving patient adherence due to increased self-administration figures. As well as these areas of lucrative opportunity, there are still several ongoing challenges that the key-thought leaders are battling to overcome such as chemical compatibility, user safety, high-volume and highly viscous formulation, and non-compliance.
Pre-Filled Syringes East Coast will once again play host to an international audience of drug delivery, medical device and PFS experts to discuss emerging trends and offer innovative solutions to the challenges facing the prefilled industry, helping attendees to secure global success for their PFS device.
The Integrated Early Drug Development Platform White PaperCovance
Is it possible to deal with the explosion of complexity in the early clinical development space? Is the traditional clinical pharmacology unit obsolete? The answers are yes and no, respectively. The optimal engine for early clinical development in the modern era is an integrated early drug development platform.
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Ajaz Hussain
Each section within P2 can have an impact on the other P2 sections and similarly other sections of a submission and to CGMP’s By recognizing this as a complex design system that involves multiple attributes, goals, constraints, multidisciplinary design teams (subsystems), different degrees of uncertainty, risk tolerance, etc., we wish to find opportunities to identify robust designs and design space that provides a sound basis for risk assessment and mitigation
The challenges of our time require a strategic approach to build the drugs and devices of the future. Our broad knowledge and long-term experience allow us to provide our customers with Innovative solutions and risk management.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
Following our past four highly successful events, this event focuses on “A Critical Guide for Successfully Conducting “6th Annual Clinical Trials Summit 2015” It gives me great pleasure in welcoming all of you to The Virtue Insight’s “6th Annual Clinical Trials Summit 2015”.
The best 7 innovation in mental healthSanityPharma
Here is proof of this every which way you look. The framework for product goodness in psychiatric PCD outcomes. They have a high-tech production facility that produces quality-oriented medications and other healthcare items.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
1. How True Open Innovation TM and its
global network can expand the opportunity
for drug development by increasing
efficiency and decreasing costs
Luca Rastelli, PhD
Boston Strategics Corporation
October, 2013
2. Pharmaceutical Industry Challenge
Continuous trend for
decreased productivity
and increased overall
investment to discover
and develop new drugs
CONFIDENTIAL
www.BostonStrategics.com
2
3. Innovation is coming from smaller Biotech
as opposed to Big Pharma
More and more, approved
compounds were born and
achieved PoC in a small,
biotech setting
CONFIDENTIAL
www.BostonStrategics.com
3
4. Big Pharma attempts of creating Open
Innovation, Biotech-like have mixed results
CEDD Center of Excellence for External Drug Discovery
CONFIDENTIAL
www.BostonStrategics.com
4
5. Big Pharma culture and structure impede
attempts to “…be more like Biotech…”
Big Pharma matrix-organization is culturally unable to support the
needed project-focus, project-based dynamics and decision-time
requirements. The functional unit-based priorities, planning (and
politics) will never be aligned with the project-based ones
Big Pharma structural complexity, both in people and physical plant
create an economical framework that does not support the correct
allocation of resources to the individualized need of a given project
At the same time, biotech-based innovation especially in Drug
Discovery and Early Development, is challenge by limited venture and
government investments.
A paradigm shift is required: what can we learn from other
industries like the Software and Social Networking
industries
CONFIDENTIAL
www.BostonStrategics.com
5
6. True Open Innovation TM
Complete Virtualization via the Creation of a
Pharmaceutical “Social” Global network
Patients
Foundation
Pharma/Biotech
Financial Resources
Academia
Concep
t
Innovative
Drug / Treatment
at Lower Cost / Risk
Physicians
Hospitals
True Open Innovation TM
Global Network
CONFIDENTIAL
www.BostonStrategics.com
6
7. Network leverage pools of intellectual
operational and financial resources Globally
Dedicated Experts
“BS Producers”
Discovery
Medicinal Chemistry
Biology (in vitro & in vivo)
Drug Metabolism (GLP)
PK/PD, Imaging
BS Global Network
External Experts
CROs and CMOs
Project
A
Analytical Chemistry (GMP)
Process Chemistry (GMP)
API Manufacturing (GMP)
Safety Pharmacology (GLP)
Toxicology (GLP)
Toxicokinetics (GLP)
Formulation (GMP)
Drug Product
Manufacturing (GMP)
IND
Clinical Studies (GCP)
Supply Chain Management (GCP)
Business Development
QA/Regulatory
NDA
Sales, Commercial
Virtual teams are assembled to move individual projects
through the Product Development phase
CONFIDENTIAL
www.BostonStrategics.com
Project
B
Project
C
7
8. True Open Innovation TM benefits
• Wider spectrum of sources for concepts, herd and metoo mentality are limited if not eliminated
• No preexisting cultural inertia
• Non-project related or project-driven priorities
• Ability to chose the resources and people that best fit the
project, no attempts to “fit” the project within only
resources and people available to a given-organization
All of this results in faster and less expensive development,
permitting more ideas/compounds to be tested
CONFIDENTIAL
www.BostonStrategics.com
8
9. Boston Strategics
• Incorporated in 2012
• Located in the Venture Development
Center on the campus of University of
Massachusetts (UMass)
• Surrounded with innovative academic
collaborators, biotech/pharmaceutical
industry partners, and major venture
capital firms
• Dedicated to establish a True Open
Innovation TM network, generating
supportive feasibility examples
working both on internal and
external projects
CONFIDENTIAL
www.BostonStrategics.com
9
10. Management Team
•Keizo Koya, PhD – CEO and Founder. 30+ years of industry experiences, 25 years in pharma
R&D. Sr. Vice President, Drug Development, Synta Pharmaceuticals (ganetespib, Hsp90 inhibitor,
elesclomol, cancer metabolism); JSC member with GSK, Roche. Vice President R&D, Shionogi
BioResearch; Director, Drug Discovery & Development, Fuji ImmunoPharmaceuticals; Head
Pharmaceutical R&D, Fuji Film USA. Led anti-cancer mitochondria-target project Harvard DFCI; Chief
Scientist, Main Res. Institute, Fuji Film, Japan.
•Eita Kitayama, MS – President and Founder. Sr. Director, Preclinical Outsourcing & Strategy,
Synta Pharmaceuticals; Senior Program Manager & Senior Scientist, Covance Laboratories; 17 years
pharma Program Manager, Study Director, Chief of GLP Office, GLP Computer System Manager,
and Laboratory Scientist in Japan.
•Luca Rastelli, PhD – Head, Business Development & Translational Strategy. 20 years
pharma/biotech oncology drug development experience; Project Leader, EMD Serono for selective cMet inhibitors and Oncology Business Opportunities; Discovery Team Lead, Sopherion (peptides for
oncology and inflammation; CuraGen, Team Lead on Abgenix collaboration to mine the Human
Genome for novel oncology therapeutic antibody targets, completed the preclinical development
phase of the immunoconjugate antibody CR011 (CDX011).
•Linda Paradiso, DVM, MBA – Head, Drug Development. 30+ years drug development experience.
Worldwide development, approval and lifecycle management of 11 marketed anti-infective and
oncology therapeutics Viracept®, Penetrex®, Omnicef®, Doxil®, DepoCyt®, Treanda , Kepivance®,
Neulasta® Aranesp®, Vectibix® and NPlate®, and 30 INDs. Executive R&D management positions;
Tanox (now Genentech), Amgen, Pfizer La Jolla, Agouron (now Pfizer), Salmedix (now
Cephalon). $30M VC raised.
CONFIDENTIAL
www.BostonStrategics.com
10
11. Example of True Open Innovation TM
Original (Pharma company):
Boston Strategic (True Open Innovation) :
$4.2M, 18 month
$1.8M, 12 month
• Strategic Development Plan
• Traditional plan vs New development plan with world-experts
• CMC-API (long processes with expensive starting material SM)
• Long GMP process vs 3 steps GMP process
• Expensive SM vs Inexpensive SM with new process at good CMO in
China
• GPM in high containment vs CMO in Canada with 40% Tax Credit
• Lyo product vs Solution product at Canadian CMO with 40% Tax Credit
• GLP Tox and DMPK
• CROs in Japan vs high quality CROs in Canada with 40% Tax Credit
• Clinical Development (P1/2a) Plan
• Company driven plan vs Academic Oncologists driven plan
CONFIDENTIAL
www.BostonStrategics.com
11
12. Example of True Open Innovation TM
• Strategic Development Plan for Accelerated Clinical
development
• Worked with network of Academic Physicians to identify
real un-met medical need and real practice-based
Standard-of-care
• Clinical plan takes compound to Approval in less than
half the time and 1/3 the cost
• Innovative approach for Prelinical development
• Taken 2 compounds through high quality preclinical
development phase with substantial savings in time and
cost
CONFIDENTIAL
www.BostonStrategics.com
12
13. Components of True Open Innovation TM
World-wide partner network
i.
ii.
iii.
Japanese company entering new therapeutic area,
Oncology, with virtual organization of only 2 people
Chinese partners for accelerated preclinical and clinical
development to be leveraged outside of China
Canadian Project management company to leverage
Canadian Tax Incentives
Strategic Alliances with Academic Institutions
i.
ii.
MD Anderson Cancer Center
Beth Israel Deaconess Medical Center
Leverage of Public/Private Resource Pools
i.
ii.
Canadian and French Tax Incentives
Collaborations with Patient-driven foundations, MMRF, LLS
CONFIDENTIAL
www.BostonStrategics.com
13
14. Long Term Vision
BS will provide a New Concept Platform for Drug R&D by
“True” Open Innovation
• Anybody could submit concepts, candidates,
and resources
• BS can “produce” any new projects by
integrating global intellectual and financial
resources of the network
• Anybody could follow BS to create new drugs
with the “true” open innovation platform
CONFIDENTIAL
www.BostonStrategics.com
14